Petros Pharmaceuticals, Inc. (PTPI) Form 10-Q — May 13, 2026
Petros Pharmaceuticals, Inc. has experienced a net loss of $987,036 for the three months ended March 31, 2026, compared to a net loss of $2,260,022 for the same period in 2025. The decrease in net loss is primarily due to a reduction in selling, general and administrative expenses, which decreased by $431,170 or 30% from $1,458,349 in 2025 to $1,027,179 in 2026. The company's cash position as of March 31, 2026, is $4,352,450, down from $5,136,722 as of December 31, 2025.
Key figures
- Eps
- 0
- Revenue
- 0
- Total Debt
- 2623135
- Cash Position
- 4352450
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.